Indeed, pre-clinical [86–89] and clinical [90] studies show therapeutic efficacy in targeting of AKT or co-targeting AKT and the androgen axis/androgen receptor in castration-recurrent PC, yet ours is the first to use isogenic PC cell lines to address how PTEN and AKT isoform affect metastatic signaling and progression. Here, AKT1 is linked to pachyonychia congenita.